26-Feb-2026 5:45 PM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday
23-Feb-2026 3:05 PM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and year ended December 31, 2025. Clinical & Operational Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi
17-Feb-2026 4:05 PM CST - Business Wire Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our
6-Jan-2026 6:30 AM CST - Business Wire Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organization, includ
4-Nov-2025 6:00 AM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences: UBS Global Healthcare Conference in Palm Beach on Monday, November 10, 2025 at 3:30pm EST Jefferies Global Healthcare Conference in Lon
20-Oct-2025 5:45 AM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025. Planned BLA Submission for Ivonescimab in Q4 2025 Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application (BLA) in order to seek approval for ivonescimab plus chemotherapy for this proposed in
17-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compared to bevacizumab plus chemotherapy
15-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data. As a reminder, the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispeci
26-Feb-2026 5:45 PM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday
23-Feb-2026 3:05 PM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and year ended December 31, 2025. Clinical & Operational Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi
17-Feb-2026 4:05 PM CST - Business Wire Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our
6-Jan-2026 6:30 AM CST - Business Wire Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organization, includ
4-Nov-2025 6:00 AM CST - Business Wire Summit Therapeutics to Present at Upcoming Investor Conferences $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences: UBS Global Healthcare Conference in Palm Beach on Monday, November 10, 2025 at 3:30pm EST Jefferies Global Healthcare Conference in Lon
20-Oct-2025 5:45 AM CST - Business Wire Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025. Planned BLA Submission for Ivonescimab in Q4 2025 Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application (BLA) in order to seek approval for ivonescimab plus chemotherapy for this proposed in
17-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III clinical study, HARMONi-GI3, to evaluate ivonescimab plus chemotherapy compared to bevacizumab plus chemotherapy
15-Oct-2025 6:00 AM CST - Business Wire Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data. As a reminder, the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispeci
